Vectura Group (LON:VEC) had its target price lowered by stock analysts at Peel Hunt from GBX 107 ($1.40) to GBX 105 ($1.37) in a note issued to investors on Tuesday. The brokerage presently has a “hold” rating on the stock. Peel Hunt’s target price would indicate a potential upside of 38.71% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Vectura Group from GBX 140 ($1.83) to GBX 110 ($1.44) and set an “overweight” rating for the company in a research report on Wednesday, January 2nd. Shore Capital restated a “hold” rating on shares of Vectura Group in a research report on Thursday, January 3rd. Finally, Numis Securities restated a “buy” rating and issued a GBX 160 ($2.09) target price on shares of Vectura Group in a research report on Monday, November 26th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of GBX 120.88 ($1.58).

LON VEC opened at GBX 75.70 ($0.99) on Tuesday. The stock has a market capitalization of $502.41 million and a price-to-earnings ratio of -7.21. Vectura Group has a 12-month low of GBX 65.85 ($0.86) and a 12-month high of GBX 107.80 ($1.41).

Vectura Group Company Profile

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Featured Article: Market Capitalization in the Stock Market

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.